HomeSearch for 'Patients'

Patients - News and Articles about commonly prescribed drugs

New antibody can scale back swelling assaults in sufferers with hereditary angioedema

Posted in News on 29th November 2018

Sufferers with hereditary angioedema expertise recurrent and generally life-threatening swelling assaults. Researchers from Charité – Universitätsmedizin Berlin have examined an antibody able to lowering the frequency of those swelling assaults by greater than 90 p.c. Outcomes from their part three trial had been revealed yesterday in JAMA, the famend Journal of the American Medical Affiliation.

Hereditary angioedema is a uncommon genetic illness characterised by painful swellings affecting the pores and skin, mucous membranes and inner organs. Assaults happen spontaneously and often final for a number of days. Swelling of the higher airways together with the throat and tongue could cause loss of life by asphyxiation. In severely affected sufferers, therapy often entails prophylactic remedy geared toward lowering the chance of life-threatening swelling. Up to now, therapies accessible for this objective usually produced extreme unwanted side effects, required a number of injections per week, or had been of restricted efficacy.

Charité-based researchers have now been in a position to present that lanadelumab, a brand new monoclonal antibody therapy, is able to lowering the frequency of swelling assaults by greater than 90 p.c. Given each two weeks by subcutaneous injection, the therapy could be self-administered by the affected person utilizing an injection pen. “This new antibody is the simplest therapy at present accessible for the prevention of swellings in sufferers with hereditary angioedema,” explains Prof. Dr. Marcus Maurer, Analysis Director of Charité’s Division of Dermatology, Venereology and Allergology and senior creator of the examine. “It is going to additionally come as an awesome aid to sufferers that this medication solely must be injected as soon as each two weeks,” he provides.

As a part of their worldwide part three trial, 125 sufferers aged 12 years or older obtained completely different dose regimens of lanadelumab or placebo for a length of 26 weeks. At the simplest dose, the antibody-based therapy lowered the month-to-month assault charge from three.5 to zero.26. Based mostly on the outcomes of this trial, the European Medicines Company’s Committee for Medicinal Merchandise for Human Use really helpful in October that lanadelumab be licensed to be used within the prevention of recurrent assaults of hereditary angioedema in sufferers aged 12 years and older. “This suggestion will inform the European Fee’s determination on a advertising authorization, which is anticipated later this 12 months,” says Prof. Maurer.

Lanadelumab is an antibody that targets a protein within the physique known as kallikrein. Within the bloodstream, kallikrein produces bradykinin, a tissue hormone that causes fluids to leak from blood vessels into tissues, inflicting swelling. In folks with hereditary angioedema, genetic modifications end in an overactivation of the kallikrein system. Lanadelumab binds kallikrein, thereby inhibiting the manufacturing of bradykinin and stopping the swelling assaults sometimes related to the illness.

Supply:

https://www.charite.de/en/service/press_reports/artikel/element/a_new_drug_to_prevent_life_threatening_swelling_attacks/

Antidepressants Improve Opposed Reactions in Surgical Sufferers

Posted in Nefazodone on 25th November 2018

PPI Initiation in Sufferers Handled With Direct Oral Anticoagulants Examined

Posted in News on 24th November 2018

Если Вы считаете, что включение ip-адреса нужного Вам интернет-ресурса в “Единый реестр…” или “Реестр доменных имен…” произошло по ошибке, или оно нарушает Ваши законные права, пожалуйста, обращайтесь непосредственно к уполномоченному органу по координатам на интернет-сайте реестра.

Перейти на сайт
Универсального сервиса проверки ограничения доступа к сайтам или страницам сайтов сети “Интернет”

Prescription Digital Therapeutic reSET Now Accessible for Sufferers With SUD

Posted in News on 21st November 2018

Если Вы считаете, что включение ip-адреса нужного Вам интернет-ресурса в “Единый реестр…” или “Реестр доменных имен…” произошло по ошибке, или оно нарушает Ваши законные права, пожалуйста, обращайтесь непосредственно к уполномоченному органу по координатам на интернет-сайте реестра.

Перейти на сайт
Универсального сервиса проверки ограничения доступа к сайтам или страницам сайтов сети “Интернет”

Novel Antiviral Pimodivir Evaluated in Sufferers With Acute Uncomplicated Influenza A

Posted in News on 17th November 2018

November 16, 2018

Pimodivir is a novel nonnucleoside PB2 inhibitor.

Pimodivir is a novel nonnucleoside PB2 inhibitor.

Pimodivir, an investigational first-in-class inhibitor of influenza virus polymerase basic protein 2 (PB2), was found to be beneficial in the treatment of acute uncomplicated influenza A virus infection in adult patients, according to the results of a Phase 2b study.

To evaluate the safety and antiviral activity of the treatment, patients in the TOPAZ trial (N=292) were randomized to receive pimodivir 300mg or 600mg, pimodivir 600mg plus oseltamivir 75mg, or placebo twice daily for 5 days; of the 292 patients included, 223 had confirmed influenza A and were treated.

Related Articles

Results showed that in patients with acute uncomplicated influenza A virus infection, pimodivir, both as monotherapy and in combination with oseltamivir, was associated with significant virologic improvements vs placebo. Moreover, the combination of pimodivir plus oseltamivir was found to result in the largest decrease in viral load. The most commonly reported adverse events were diarrhea and nausea, which were mild to moderate in severity; overall, the treatment was well-tolerated.

“While only trends toward a clinical benefit were observed in this study, owing to a low power to detect statistically significant differences, these trends, along with the favorable safety and dosing profiles, provide an overall compelling case for further investigation,” concluded the authors.

For more information visit academic.oup.com.

Scroll down to see the next article